

Special Issue

Recent Advances in the Field of Metastatic Melanoma

Message from the Guest Editor

Cutaneous melanoma represents one of the most aggressive and difficult to treat forms of human cancer, with a worldwide incidence that has steadily increased over the past half a century. Although the majority of melanomas are successfully treated with surgical excision, most patients with metastatic melanoma do not benefit from surgery due to metastasis. Despite more therapeutic advances, metastatic melanoma still has poor long-term outcomes. Targeted therapies such as BRAF and MEK inhibitors have dramatically improved the prognosis of patients with metastatic melanoma bearing specific gene alterations. However, acquired resistance rapidly develops, hindering its durable efficacy. In recent years, immunotherapy has demonstrated a durable response in half of the patients with metastatic melanoma. At the same time, half of these patients experience side effects with severe autoimmune adverse events. Therefore, uncovering metastatic melanoma characteristics and new therapeutic strategies is critical for fighting the deadliest metastatic melanoma diseases.

Guest Editor

Dr. Yanlin Yu

Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute (NCI-CCR), Bethesda, MD 20852, USA

Deadline for manuscript submissions

closed (25 June 2024)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/141157

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/

[cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).